US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Research & Development: market research reports

The term research and development (R&D) refers to work that is done in order to better understand the nature, function or understanding of a topic or product in order to gain knowledge and find new applications for existing products or to develop new and innovative products. This is usually performed by corporations, government agencies, and research or academic institutions.

New product design and development is essential for the survival and growth of many companies, as markets and consumers’ tastes are fickle and the competition can be fierce. In order to stay relevant in a fast changing marketplace, firms have to constantly revise and expand their range of product offerings. Therefore, research and development is of great economic importance as companies fight to maintain their market share, though it may mean forgoing current profits in favor of potential future performance and returns.

Research and development is most often associated with the technology industry, as well as with science and in particular with healthcare and the development of new pharmaceuticals, diagnostics or medical devices that are safe and effective. For instance, drug makers must constantly search for the next big blockbuster drug, since the products they currently have on the market will eventually lose their patent protection and be vulnerable to generic competition. So they spend huge amounts of money on R&D because without a promising drug pipeline their revenue stream will ultimately dry up.

RSS Feeds

Research & Development market research reports and industry analysis

< prev 1    3  4  5  6  7  8  9  10  
PHARMACEUTICAL MARKET INDIA 2014-2020 : Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), Biosimilars, Generics & Vaccines
8/1/2014 | published by: Kelly Scientific Publications
... Biosimilars, Generics & Vaccines” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle ...  |  read more...
USD 2,000
Global Retinal Vein Occlusion Market : 2014-2018
7/23/2014 | published by: TechNavio - Infiniti Research Ltd.
... AG, F. Hoffmann-La Roche Ltd., Novartis AG and Regeneron Pharmaceuticals Inc. Other prominent vendors in the market are: Alimera Sciences, Bristol-Myers Squibb, NicOx, Santen Pharmaceutical and Valeant Pharmaceuticals. Commenting on the report, an analyst from ...  |  read more...
USD 2,500
Global Parkinson's Disease Market : 2014-2018
7/23/2014 | published by: TechNavio - Infiniti Research Ltd.
... GlaxoSmithKline plc, Novartis AG and Teva Pharmaceutical Industries Ltd. Other prominent vendors in this market are: Abbvie Inc., Akorn Inc., Astellas Pharma Inc., Desitin Arzneimittel GmbH, Endo International plc, F. Hoffmann-La Roche Ltd., H. Lundbeck ...  |  read more...
USD 2,500
Endometrial Cancer - Pipeline Review, H2 2014
7/22/2014 | published by: Global Markets Direct
... therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
VBI Vaccines - Product Pipeline Review - 2014
7/22/2014 | published by: Global Markets Direct
... provides comprehensive information on the current therapeutic developmental pipeline of VBI Vaccines’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. ...  |  read more...
USD 1,500
Proteins in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... 667 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 190 drugs. Proteins In Oncology Drug Pipeline Update lists ...  |  read more...
USD 6,746
The Latest Sales Figures in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... global pharmacuetical companies to progressive biotech companies. The analysis leverages the power of BioSeeker's 1stOncology intelligence which combines company disclosed product sales and detailed drug development information. The results is not only a unique insight ...  |  read more...
USD 4,478
Radiation Therapy in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... 725 developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 140 drugs. Radiation Therapy In Oncology Drug Pipeline Update ...  |  read more...
USD 6,746
TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... in 1411 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 227 drugs. Tgf-Beta Receptor Signaling Pathway In Oncology ...  |  read more...
USD 6,746
T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... cell receptor signaling. There are today 246 companies plus partners developing 359 T cell receptor pathway targeting drugs in 1278 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number ...  |  read more...
USD 6,746
Apoptosis in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... cancer cells. There are today 347 companies plus partners developing 431 apoptotic drugs in 1996 developmental projects in cancer. In addition, there are 10 suspended drugs and the accumulated number of ceased drugs over the ...  |  read more...
USD 6,746
Nucleic Acid Therapies in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... are today 229 companies plus partners developing 291 nucleic acid therapy drugs in 636 developmental projects in cancer. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last ...  |  read more...
USD 6,746
Orphan Drugs in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... not only to those cancer indications in which drugs are being granted orphan drug status, but also detailed insights in to their mechanism of action and developmental strategy. The orphan drug designation is designed to ...  |  read more...
USD 6,746
Leukemia Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 127 drugs. Leukemia Drug Pipeline Update lists all drugs and gives ...  |  read more...
USD 6,746
IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 28 drugs. Il-9 Signaling Pathway In Oncology Drug Pipeline Update ...  |  read more...
USD 4,496
ID Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... other family members inhibiting their DNA binding capacity. This family of proteins is comprised of IDs 1, 2, 3 and 4. There are today 94 companies plus partners developing 96 ID pathway targeting drugs in ...  |  read more...
USD 2,246
IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... drugs in 1307 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 152 drugs. Il-2 Signaling Pathway In Oncology ...  |  read more...
USD 6,746
IL-4 Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... 724 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 81 drugs. Il-4 Signaling Pathway In Oncology Drug Pipeline ...  |  read more...
USD 6,746
Colorectal Cancer Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years. There are today 317 companies ...  |  read more...
USD 6,746
Cytokine Therapy in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... accumulated number of ceased drugs over the last years amount to another 8 drugs. Cytokine Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ...  |  read more...
USD 4,496
Oncology Drug Pathway Analyzer (Standard Version)
7/15/2014 | published by: BioSeeker Group AB
... their pathways are the critical link between drugs and their role in the treatment of cancer. This highly unique interactive tool is based on BioSeeker’s linking of hundreds of drug targets in many different types ...  |  read more...
USD 31,050
Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 223 drugs. Androgen Receptor Signaling Pathway In Oncology Drug Pipeline ...  |  read more...
USD 6,746
Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... three successful drugs are just the top of an emerging line of therapy. Given the fact that they all target tyrosine kinases and that kinase mutations can cause patients to become resistant to these drugs, ...  |  read more...
USD 6,746
TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... in 2048 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 257 drugs. Tnf-Alpha Signaling Pathway In Oncology Drug ...  |  read more...
USD 6,746
Lung Cancer Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe ...  |  read more...
USD 6,746
< prev 1    3  4  5  6  7  8  9  10